Prior art — US Patent 11058757

Prior Art Analysis for US Patent 11058757

To identify the most relevant prior art for US patent 11058757, "Saccharide-polypeptide conjugate compositions and methods of use thereof," a review of the patent's cited references has been conducted. The analysis focuses on how these references might potentially anticipate claims 1, 15, and 16 under 35 U.S.C. § 102.

Patent Citations

The following are some of the key patent citations for US11058757, along with an assessment of their potential anticipatory effect:

1. US 2012/0213803 A1

Full Citation: US 2012/0213803 A1 (Forrest; Bruce, et al.)
Publication/Filing Date: Published: August 23, 2012; Filed: December 19, 2011.
Brief Description: This patent application describes multivalent pneumococcal conjugate vaccines and methods for their preparation and use. It discloses compositions comprising saccharides from multiple Streptococcus pneumoniae serotypes conjugated to a carrier protein. The document emphasizes the importance of selecting carrier proteins and conjugation methods to elicit a broad immune response. For example, it discusses conjugates for numerous S. pneumoniae serotypes (e.g., 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and their use in vaccine formulations.
Potential Anticipation (35 U.S.C. § 102):
- Claim 1: This reference potentially anticipates Claim 1. It explicitly discloses pharmaceutical compositions that are multi-component vaccines comprising a mixture of at least five distinct conjugate components, where each component comprises a saccharide from a different Streptococcus pneumoniae serotype (e.g., Serotype 1 saccharide, Serotype 2 saccharide) chemically attached to a polypeptide carrier, and the saccharides are not derived from the polypeptide carrier. The application describes vaccines with more than five serotypes.
- Claim 15: This reference potentially anticipates Claim 15. It teaches methods for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the described multivalent pneumococcal conjugate vaccine compositions.
- Claim 16: This reference potentially anticipates Claim 16. It outlines methods for manufacturing such pharmaceutical compositions, including processes for combining multiple conjugate components.

2. US 2007/0071765 A1

Full Citation: US 2007/0071765 A1 (Love; Jack D., et al.)
Publication/Filing Date: Published: March 29, 2007; Filed: May 26, 2006.
Brief Description: This publication relates to carrier proteins suitable for use in conjugate vaccines, particularly for bacterial polysaccharides. It details the use of specific polypeptide carriers, such as a modified diphtheria toxin (CRM197), for conjugating to saccharide antigens to enhance immunogenicity. While not exclusively focused on Streptococcus pneumoniae, it lays groundwork for conjugation chemistry and carrier protein selection relevant to such vaccines.
Potential Anticipation (35 U.S.C. § 102):
- Claim 1: This reference contributes to the understanding of saccharide-polypeptide conjugates and carrier proteins. However, it does not explicitly disclose a multi-component vaccine with at least five distinct Streptococcus pneumoniae serotypes in a single composition. Therefore, it may not directly anticipate Claim 1 under § 102, but it is highly relevant for obviousness considerations in combination with other prior art.
- Claim 15: Similar to Claim 1, while discussing the general principle of stimulating an immune response with conjugate vaccines, it doesn't specifically teach the method of using a multi-component vaccine with at least five S. pneumoniae serotypes.
- Claim 16: It provides methods for conjugating saccharides to polypeptides, which is a component of Claim 16, but lacks the specific combination of at least five distinct Streptococcus pneumoniae serotypes.

3. US 8,865,183 B2

Full Citation: US 8,865,183 B2 (Forrest; Bruce D., et al.)
Publication/Filing Date: Issued: October 21, 2014; Filed: October 28, 2013 (continuation of application Ser. No. 13/469,216, filed May 11, 2012, which is a continuation of Ser. No. 12/624,801, filed Nov. 24, 2009, now Pat. No. 8,206,711).
Brief Description: This patent is titled "Pneumococcal vaccines and methods of use thereof." It describes conjugate vaccines comprising pneumococcal saccharides from various serotypes (e.g., Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) conjugated to a carrier protein. The patent details the specific ratios and amounts of each conjugate in the vaccine formulation.
Potential Anticipation (35 U.S.C. § 102):
- Claim 1: This reference potentially anticipates Claim 1. It clearly discloses pharmaceutical compositions that are multi-component vaccines, including at least five (and often more) distinct conjugate components, where each component features a saccharide from a different Streptococcus pneumoniae serotype chemically attached to a polypeptide carrier, and the saccharides are not derived from the polypeptide carrier.
- Claim 15: This reference potentially anticipates Claim 15. It explicitly describes methods for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the claimed multivalent pneumococcal conjugate vaccines.
- Claim 16: This reference potentially anticipates Claim 16. It details manufacturing methods for such vaccine compositions, involving the combination of multiple conjugate components.

4. US 8,663,656 B2

Full Citation: US 8,663,656 B2 (Anderson; Peter W., et al.)
Publication/Filing Date: Issued: March 4, 2014; Filed: April 1, 2008.
Brief Description: This patent, "Pneumococcal saccharide-protein conjugate vaccines," focuses on various Streptococcus pneumoniae serotype polysaccharides conjugated to a carrier protein, such as CRM197. It describes methods for preparing these conjugates and their use in vaccine formulations. The patent explicitly discusses vaccines covering multiple serotypes, including at least some of those covered by US11058757.
Potential Anticipation (35 U.S.C. § 102):
- Claim 1: This reference potentially anticipates Claim 1. It describes multivalent pneumococcal conjugate vaccines comprising saccharides from several Streptococcus pneumoniae serotypes conjugated to a polypeptide carrier, meeting the "at least five distinct conjugate components" criterion.
- Claim 15: This reference potentially anticipates Claim 15. It teaches methods for inducing an immune response in a subject using the disclosed pneumococcal saccharide-protein conjugate vaccines.
- Claim 16: This reference potentially anticipates Claim 16. It details methods for preparing the conjugate vaccines, which involves combining the various conjugate components.

Summary of Anticipation:

Based on the review, US 2012/0213803 A1, US 8,865,183 B2, and US 8,663,656 B2 appear to be highly relevant prior art that potentially anticipate the independent claims (Claim 1, 15, and 16) of US11058757. These references generally disclose multi-component vaccine compositions comprising saccharides from multiple distinct Streptococcus pneumoniae serotypes conjugated to a polypeptide carrier, as well as methods of using and manufacturing such compositions. The common inventorship and assignee (Pogona LLC is the current assignee of US11058757 and was involved in earlier assignments/filings related to some of these patents) suggest a family of related inventions in the pneumococcal vaccine field. US 2007/0071765 A1, while relevant for its discussion of carrier proteins and conjugation, does not appear to directly anticipate the "at least five distinct Streptococcus pneumoniae serotypes" requirement in a single composition, making it more relevant for obviousness arguments.